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Purpose. To determine if recent preoperative exposure to n-acetylcysteine (NAC), Mucomyst, increases postoperative blood loss
in cardiac surgery patients. Methods. Retrospective review of cardiac surgery patients who underwent a cardiac catheterization
within four days of surgery and whose serum creatinine was ≥1.0mg/dL. The study groups were those who received NAC in
the pericatheterization period versus those who did not. The primary endpoint was postoperative chest tube output at 24, 48,
and 72 hours. Secondary endpoints included number of transfusions and other bleeding parameters. Results. Mean blood loss
in the ﬁrst 24 hours was 962 ± 595mL in the treatment group (n = 79) and 1,178 ± 788mL in the control group (n = 106),
P = .040. Blood loss between groups at 48 (366 ± 318mL versus 412 ± 363mL, P = .382) and 72 (194 ± 300mL versus 176
± 224mL, P = .643) hours was not signiﬁcantly diﬀerent. There were no signiﬁcant diﬀerences in postoperative transfusions
or other bleeding parameters. Conclusions. Preoperative exposure to NAC did not increase postoperative blood loss or negatively
aﬀect other bleeding parameters.
1.Introduction
Contrast agents used for diagnostic procedures such as
cardiac angiography can lead to contrast-induced nephropa-
thy [1]. N-acetylcysteine (NAC), Mucomyst, an amino
acid derived from cysteine, causes vasodilation, increases
glutathione production, and has antioxidant properties all
of which may reduce or prevent this kidney damage [1–3].
Currently, evidence is mixed as to the eﬀectiveness of NAC
at preventing contrast-induced nephropathy. Several studies,
including Tepel et al. and the APART trial, found NAC to be
an eﬀective treatment to prevent renal damage from contrast
media [1–5]. However, results showing NAC to be ineﬀective
at preventing contrast-induced nephropathy have also been
found [6–8].
Despite the conﬂicting evidence concerning NAC’s eﬀec-
tiveness, it is often used prior to contrast agents due to
its low cost and relatively benign side eﬀect proﬁle. NAC
administration has also been studied intraoperatively due
to its potential to help reduce inﬂammation and ischemia-
reperfusion organ damage associated with cardiac surgery
[9]. However, recently NAC’s eﬀect on blood loss and
coagulation has been questioned [9, 10]. Studies have found
that intraoperative use of NAC impairs postoperative hemo-
dynamics resulting in: increased blood loss, increased trans-
fusions, and increased risk of reoperation [9, 10]. Whether
NAC use in the perioperative setting may also contribute to
potential increases in blood loss is not known. However, it
is necessary to evaluate NAC in this population, as many
patientsundergocoronaryangiographyimmediatelypriorto
cardiac surgery.
T h ep r i m a r yo b j e c t i v eo ft h i ss t u d yw a st od e t e r m i n e
the eﬀects of preoperative NAC exposure on postoperative
chest tube blood loss at 24, 48, and 72 hours after cardiac
surgery. Secondary objectives included the eﬀect of recent
NAC exposure on ﬁrst postoperative PT, hemoglobin (Hgb),
hematocrit (Hct), platelets, and number of postoperative
blood transfusions in the ﬁrst 72 postoperative hours.
2.MaterialsandMethods
This retrospective chart review was conducted at a regional
411-bed not for proﬁt community hospital. Data were2 International Journal of Vascular Medicine
collected from patients’ medical records accessed through
the medical records department of the hospital. Patients
were included for chart review if they presented for cardiac
surgery between June 1, 2006 and June 1, 2009, were >18
years old, had a precardiac catheterization serum creatinine
(Scr) measurement of ≥1.0mg/dL, and underwent cardiac
catheterization within four days of cardiac surgery. Patients
undergoing emergent cardiac surgery were excluded.
Patients in the NAC treatment arm received oral NAC
600mg twice daily for two days, beginning the day before
cardiaccatheterization,forkidneyprotectionassociatedwith
contrast agents. NAC had to have been administered within
four days of cardiac surgery to be included in this study.
Patients in the NAC group also received saline hydration
and may have received concomitant bicarbonate therapy.
Patients in the control group received saline hydration and
may have received bicarbonate therapy prior to cardiac
catheterization.
The primary outcome was blood loss between groups
measured as chest tube output at 24, 48, and 72 hours
after surgery in patients who received NAC within 4 days of
cardiac surgery compared to those who did not. Secondary
outcomes measured were ﬁrst postop PT time, lowest Hgb,
lowest Hct, and platelet count at 24, 48, and 72 hours after
surgery, number of postop blood transfusions, and length of
hospital stay.
The time period utilized for data collection was specif-
ically chosen as this was a period in time where cardiac
catheterization patients were all receiving the same peri-
procedural protocol with regards to medications. Thus, all
patients who met inclusion criteria during the designated
study period were screened for potential study inclusion.
StatisticalanalysiswascompletedusingSPSS(SPSSstatistics,
version17).Demographicdatawereanalyzedusingthet-test
and Chi Square where appropriate. Preoperative character-
istics and primary and secondary objectives were analyzed
using the t-test. A P value <. 05 was considered signiﬁcant.
This study was approved by the hospital’s Institutional
Review Board.
3. Results andDiscussion
3.1.Results. Onethousandtwohundredthirteenchartswere
screened for potential study inclusion, and one hundred
eighty-ﬁve met inclusion criteria. Seventy-nine patients
comprised the NAC treatment group, and one hundred six
patients comprised the control group. See Figure 1.
Demographic data are presented in Table 1.G r o u p sw e r e
similar at baseline with the exception of history of diabetes,
history of hypertension, and type of cardiac surgery. Patients
in the NAC group were more likely to have a history of
diabetes and hypertension while patients in the control
group were more often CABG only procedures.
Preoperative proﬁles are presented in Table 2. Patients
treated with NAC had higher serum creatinine mea-
surements prior to cardiac catheterization and before
surgery. NAC-treated patients also had signiﬁcantly lower
hemoglobin and hematocrit levels prior to surgery.
Table 1: Patient demographics.
Variable
N-
acetylcysteine
group
(n = 79)
Control
group
(n = 106)
P Value
Age in yearsa 67.3 ± 9.1 65.5 ± 10.8 .233
Gender .456
Males 72.2% 79.2%
Females 27.8% 20.8%
Baseline ADP inhibitor
use 5.6% 4.7% .451
Baseline aspirin use 92.4% 96.2% .508
History of diabetes 58.2% 35.8% .007
History of dyslipidemia 83.3% 82.1% .451
History of hypertension 86.1% 75.5% .029
Type of surgery .001
CABG only 70.9% 85.8%
Valve only 6.3% 5.7%
CABG + Valve 7.6% 4.7%
Otherb 15.2% 3.8%
Height (cm)a 172 ± 9.9 172 ± 9.0 .952
Weight (kg)a 88.9 ± 22.9 88.5 ± 19.1 .908
aMean ± standard deviation.
bTransmyocardial revascularization (TMR) or MAZE procedure.
CABG: coronary artery bypass graft.
ADP: adenosine diphosphate.
Table 2: Preoperative (Pre-op) characteristics.
Endpoint
N-
acetylcysteine
group
(n = 79)
Control
group
(n = 106)
P Value
Days between cath and
surgery 2.05 ± 1.2 1.91 ± 1.1 .398
Precath Scr (mg/dL) 1.7 ± 1.5 1.2 ± 0.3 <.005
Preop Scr (mg/dL) 1.6 ± 1.4 1.2 ± 0.4 .002
Preop PT time (secs) 10.7 ± 1.1 10.5 ± 0.9 .284
Preop Hgb (g/dL) 12.3 ± 1.6 13.2 ± 2.0 .001
Preop Hct (%) 36.6 ± 4.3 39.2 ± 5.2 <.005
Preop platelets
(×103 mm3) 201 ± 54 209 ± 66 .372
Received precath
hydration ≥ 75mL/hr 22 25
Received precath bicarb 5 2
Received precath
hydration and bicarb 10
Cath: catheterization.
Scr: serum creatinine.
PT: prothrombin time.
Hgb: hemoglobin.
Hct: hematocrit.
Primary endpoint data are presented in Table 3. Patients
treated with NAC lost less blood in the ﬁrst 24 hour
postoperative period. Blood loss in the ﬁrst 24 hoursInternational Journal of Vascular Medicine 3
Table 3: Primary Endpoints.
Endpoint
N-
acetylcysteine
group
(n = 79 )
Control
group
(n = 106)
P Value
Chest tube output in
ﬁrst 24 hours (mL) 962 ± 577 1178 ± 788 .040
Chest tube output in
second 24 hours (mL) 366 ± 318 412 ± 363 .382
Chest tube output in
third 24 hours (mL) 194 ± 300 176 ± 224 .643
Table 4: Secondary Endpoints.
Endpoint
N-
acetylcysteine
group
(n = 79)
Control
group
(n = 106)
P Value
First postop PT time
(secs) 15.9 ± 3.2 16.6 ± 3.6 .196
Lowest Hgb in ﬁrst 24
hrs (g/dL) 8.4 ± 1.3 8.8 ± 1.6 .088
L o w e s tH g bi ns e c o n d2 4
hrs (g/dL) 8.7 ± 1.1 8.9 ± 1.1 .227
Lowest Hgb in third 24
hrs (g/dL) 9.0 ± 1.0 9.2 ± 1.0 .132
Lowest Hct in ﬁrst 24 hrs
(%) 25.0 ± 3.7 26.0 ± 4.7 .075
Lowest Hct in second 24
hrs (%) 25.9 ± 3.3 26.6 ± 3.3 .161
Lowest Hct in third 24
hrs (%) 26.8 ± 3.2 27.6 ± 3.2 .100
Lowest platelet count in
ﬁrst 24 hrs (×103/mm3) 116 ± 43 114 ± 35 .735
Lowest platelet count in
second 24 hrs
(×103/mm3)
122 ± 44 116 ± 39 .283
Lowest platelet count in
third 24 hrs (×103/mm3) 139 ± 50 127 ± 49 .121
Number of postop
transfusions 2.2 ± 2.5 2.3 ± 2.4 .653
Postop hospital stay
(days) 8.8 ± 8.8 7.6 ± 5.1 .252
PT: prothrombin time.
Hgb: hemoglobin.
Hct: hematocrit.
was 962 ± 577mL in the NAC treatment group and 1,178
± 788mL in the control group which was statistically
signiﬁcant(P-value=.040).Bloodlossbetweenthetreatment
and control groups was not signiﬁcantly diﬀerent during the
second and third 24 hour periods.
Secondary endpoints are presented in Table 4. No signif-
icant diﬀerences were observed between groups.
3.2. Discussion. Because of NAC’s antioxidant properties, it
has been evaluated for its potential to decrease inﬂammation
1,213 patient charts screened
185 patients included
NAC treatment
group
(n = 79)
Control group
(n = 106)
Figure 1: Study arms.
during surgery [10]. However, several studies have found the
use of intraoperative NAC to be associated with increased
blood loss and need for transfusions [9, 10]. Little is
known about the mechanism of this potential impairment
in hemostasis, and it is also unknown whether preoperative
exposure to NAC will also put patients at risk for increased
blood loss. The present study found that NAC, within 4
days of cardiac surgery, was not associated with increased
blood loss measured as chest tube output. Patients treated
with NAC lost less blood in the ﬁrst 24 hours after surgery
than patients who did not receive preoperative NAC. This
study also showed similar blood loss between groups at 48
and 72 hours after surgery, similar PT results, hemoglobin,
hematocrit, platelet counts, number of transfusions, and
lengthofhospitalstaysuggestingthatNACdidnotnegatively
aﬀect hemostasis.
Study patients were similar at baseline. However, more
patients in the NAC group had a history of diabetes and
hypertension. These conditions may have worsened patient’s
kidneyfunctionthusindicatingtheneedforprophylacticuse
of NAC. Also, patients treated with NAC had higher serum
creatinine levels prior to cardiac catheterization and cardiac
surgery. This diﬀerence between groups is understandable
given those patients with elevated serum creatinine are those
in need of protection from further nephropathy and there-
forereceiveNAC.Themeanchangeinserumcreatininefrom
baseline to time of discharge was not signiﬁcantly diﬀerent
between groups P = .769. There was a 0.011 ± 0.211mg/dL
mean change in serum creatinine for the NAC group and
an 0.004 ± 0.175mg/dL mean change in the control group.
Thus, indicating NAC was eﬀective in preventing contrast-
induced nephropathy in these patients. In addition, patients
treated with NAC had signiﬁcantly lower hemoglobin and
hematocrit levels before surgery, but this did not translate
into lower hemoglobin and hematocrit levels postoperatively
or an increased number of transfusions.
These results diﬀer from previous studies, and several
factorsmayhavecontributedtotheseﬁndings.Instudiesthat
havefoundanassociation betweenNACandincreasedblood4 International Journal of Vascular Medicine
loss, NAC was given intravenously during surgery compared
to the population in this study who received oral NAC prior
to cardiac surgery. Both Wijeysundera et al. and Niemi et al.
utilized IV bolus and IV infusions for NAC administration
whereas patients in our study received NAC orally. Also, in
the two studies by Wijeysundera et al. and Niemi et al.,
NAC was administered in the immediate preoperative period
[9, 10]. The study by Wijeysundera et al. administered an
NAC bolus immediately following induction of anesthesia
and then began a continuous NAC infusion which ran
during cardiac surgery and for 4 hours following the end
of cardiopulmonary bypass [9]. Niemi et al. administered
NAC also as a bolus immediately following anesthesia
induction followed by an NAC continuous infusion for 24
hours [10]. This is in contrast to our study where patients
could have received NAC anytime within 4 days of cardiac
surgery. Whether this diﬀerence in route and timing of
NAC administration accounts for the diﬀerence in bleeding
outcomes is unknown. The dosage of NAC also varied
between studies. Larger doses were used in the studies which
found NAC to be associated with increased bleeding loss.
Wijeysunderaetal.studiedadoseof100mg/kggivenIVover
30minutesfollowedbyaninfusionof20mg/kg/hrwhichwas
continued until 4 hours after cardiopulmonary bypass, and
Niemi et al. gave a 150mg/kg bolus over 20 minutes followed
by 150mg/kg infusion which was continued for 24 hours
[9, 10]. Both of the previous studies found an association
between NAC use and increased blood loss. These doses are
incontrasttothisstudywherepatients received600mgtwice
daily the day before and the day of cardiac catheterization,
and this study was not associated with increased blood
loss. However, whether NAC’s eﬀect on hemostasis is dose
related is not known and could present an area for further
study.
This study has several limitations. The study was a
retrospective chart review and thus is limited to previously
recorded data. This may have introduced bias due to
incomplete documentation. Also, our sample size was small,
and the time frame for use of NAC in the preoperative
setting is not well established in the current literature. It
is possible that our results may have changed if we had
limited the preoperative NAC dosage window to less than 4
days. The diﬀerence in route of administration and dose of
NAC administered between this study and previous studies
also must be considered when interpreting these results.
This study investigated the oral administration of NAC, at
600mg twice daily, as is the protocol at our institution which
did not match the intravenous weight-based dosing used
in the studies which found an association between NAC
and increased bleeding. Future studies should prospectively
investigate further whether larger doses of NAC, intravenous
administration, or length of time from NAC administration
till surgery aﬀects blood loss. In addition, there were
some diﬀerences in baseline characteristics between our
groups. Patients treated with NAC were more likely to
have a history of diabetes, history of hypertension, and
elevated serum creatinine. Although it is to be expected that
patients treated with NAC have baseline renal insuﬃciency
compared to patients not selected to receive this therapy,
these were still statistically signiﬁcant diﬀerences between
groups.
Due to these limitations and based on having several
unanswered questions regarding NAC and blood loss, such
as diﬀerences between routes, doses, and time period till
cardiac surgery, NAC should be studied further to assess its
aﬀects on blood loss and the safety of its use in the peri- and
intraoperative period.
4. Conclusions
PreoperativeexposuretoNACdidnotincreasepostoperative
blood loss in the ﬁrst 72 postoperative hours in the cardiac
surgery patient. Furthermore, NAC did not negatively aﬀect
PT time, hemoglobin, hematocrit, platelets, or number of
transfusion requirements.
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